Plasma pS129-α-Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson’s Disease

CSF and blood biomarkers for Parkinson's disease

(2019) Lucilla Parnetti et al.   LANCET NEUROLOGY

Plasma Biomarkers Differentiate Parkinson’s Disease From Atypical Parkinsonism Syndromes

(2018) Chin-Hsien Lin et al.   Frontiers in Aging Neuroscience

Plasma α-synuclein predicts cognitive decline in Parkinson’s disease

(2017) Chin-Hsien Lin et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson’s disease

(2016) Jian Ding et al.   JOURNAL OF NEURAL TRANSMISSION

Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles

(2016) Shieh-Yueh Yang et al.   JOURNAL OF NANOBIOTECHNOLOGY

Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials

(2014) Markus Mandler et al.   ACTA NEUROPATHOLOGICA

Mortality in Parkinson's disease: A systematic review and meta-analysis

(2014) Angus D. Macleod et al.   MOVEMENT DISORDERS

Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease

(2014) Anke A. Dijkstra et al.   MOVEMENT DISORDERS

Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies

(2013) David J. Irwin et al.   NATURE REVIEWS NEUROSCIENCE

A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson's disease

(2013) Penelope G. Foulds et al.   Scientific Reports

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines

(2012) Irene Litvan et al.   MOVEMENT DISORDERS

Naturally occurring  -synuclein autoantibody levels are lower in patients with Parkinson disease

(2012) D. Besong-Agbo et al.   NEUROLOGY

Pathological  -Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice

(2012) K. C. Luk et al.   SCIENCE

Phosphorylated  -Synuclein in Parkinson's Disease

(2012) Y. Wang et al.   Science Translational Medicine

Biofunctionalized Magnetic Nanoparticles for Specifically Detecting Biomarkers of Alzheimer’s Disease in Vitro

(2011) Che-Chuan Yang et al.   ACS Chemical Neuroscience

Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson’s disease

(2011) Jinxia Zhou et al.   ACTA NEUROPATHOLOGICA

Nigral pathology and parkinsonian signs in elders without Parkinson disease

(2011) Aron S. Buchman et al.   ANNALS OF NEUROLOGY

CSF biomarkers in neurodegenerative diseases

(2011) Niklas Mattsson   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Genome-wide association study reveals genetic risk underlying Parkinson's disease

(2009) Javier Simón-Sánchez et al.   NATURE GENETICS

Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease

(2009) S. Hoops et al.   NEUROLOGY

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results

(2008) Christopher G. Goetz et al.   MOVEMENT DISORDERS

Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood

(2008) Robin Barbour et al.   Neurodegenerative Diseases